At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,208 enrolled
Drug / intervention
CD5789 (trifarotene) 50μg/g cream +1 moredrug
Likely dose
CD5789 (trifarotene) 50μg/g creamfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris
In Brief
A Phase 3 clinical trial evaluating CD5789 (trifarotene) 50μg/g cream and Placebo cream for Acne Vulgaris. Completed, enrolled 1,208 participants across 124 sites in 5 countries.
Detailed Summary
Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesCanada, Germany, Hungary, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartNov 2015
Primary CompletionNov 2017
TodayJul 2026
First PostedOct 2, 2015
Enrollment StartNov 30, 2015
Primary CompletionNov 14, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.8 years ago
Interventions
CD5789 (trifarotene) 50μg/g creamdrug
CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
Placebo creamdrug
Placebo cream applied once daily for 12 weeks